NCT05787613View on ClinicalTrials.gov

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

July 31, 2027

Conditions
NSCLC Stage IV
Interventions
DRUG

HLX26

Anti-LAG-3 monoclonal Antibody Injection

DRUG

Serplulimab

anti-PD-1 humanized monoclonal antibody injection

DRUG

Chemotherapy drug

non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.

DRUG

Placebo

placebo

Trial Locations (3)

200032

Fudan University Shanghai Cancer Center, Shanghai

Unknown

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY